ERBB2 and breast cancer: Data support a potential role for this protein as a single biomarker for classification of breast cancer subtypes, since its expression is indicative of a negative receptor status/resistance to receptor-dependent treatments with respect to ER, PR, AR and HER2 in breast cancer.